You have searched for "CGS-CIMB"
Showing 911-920 of 979
KUALA LUMPUR: CGS-CIMB Equities Research is retaining its Add call for Duopharma Biotech with an unchanged target price of RM3.67 due to the potential long-term earnings prospects from the development of vaccine manufacturing capabilities, which is a key rerating catalyst.
PETALING JAYA: Banks will likely again face another round of modification losses as a result of the automatic loan moratorium that just started, but this time, the losses are not expected to hit them as much as the first time.
KUALA LUMPUR: CGS-CIMB Equities Research views environmental, social and governance (ESG) risks for Tenaga Nasional Bhd as opportunities given the rapid growth in renewable energy (RE).
KUALA LUMPUR: CGS-CIMB Equities Research views Malayan Banking Bhd (Maybank) as a clear leader in adopting environmental, social and governance (ESG) as its exposure to ESG vulnerable sectors only accounted for 5.4% of its total loans at end-March 2021.
Carbon emissions, electricity affordability major thrusts
PETALING JAYA: Many companies are committing to a more sustainable future. Likewise, Malayan Banking Bhd (Maybank) has earmarked long-term sustainability as one of its key strategic priorities.